NRx Pharma files ANDA for preservative-free IV ketamine; market at $750M

NRX Pharmaceuticals, Inc.

Filed ANDA for NRX-100 (preservative-free IV ketamine) with FDA; seeks priority review due to drug shortage.
Ketamine market currently $750M, projected to reach $3.35B globally by 2034.
Plans citizen petition to remove benzethonium chloride from all IV ketamine products.
Complements ongoing NDA for suicidal depression; PDUFA target late 2025; FDA waived $4.3M fee.
Patent protection sought through 2045; Fast Track designation previously granted.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.